OncoMatch/Clinical Trials/NCT06831370
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Is NCT06831370 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Brentuximab Vedotin and Doxorubicin for hodgkin lymphoma.
Treatment: Brentuximab Vedotin · Doxorubicin · Vinblastine · Dacarbazine — The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a test to check how well a participant's lungs work. Each participant will undergo a final health status check 2 months after the last treatment with brentuximab vedotin plus AVD.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immunosuppressive chemotherapy
Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose
Cannot have received: therapeutic radiation
Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose
Cannot have received: immunotherapy
Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose
Cannot have received: antibody-drug conjugate (brentuximab vedotin)
Previously treated with brentuximab vedotin
Lab requirements
Blood counts
Absolute neutrophil count ≥1,000/μL (unless HL marrow involvement); Platelet count ≥75,000/μL (unless HL marrow involvement); Hemoglobin ≥8 g/dL
Kidney function
Serum creatinine <2.0 mg/dL and/or creatinine clearance >30 mL/min (Cockcroft-Gault Equation)
Liver function
Total bilirubin <1.5 x ULN unless due to Gilbert syndrome; ALT or AST <3.0 x ULN (up to 5x ULN if due to HL in liver); moderate or severe hepatic disease excluded based on Child-Pugh criteria
Cardiac function
Left-ventricular ejection fraction <50% within 6 months before first dose excluded; NYHA Class 3 or 4 heart failure excluded; evidence of current uncontrolled cardiovascular conditions (arrhythmias, CHF, angina, ECG evidence of acute ischemia or active conduction system abnormalities) excluded; myocardial infarction within 2 years of enrollment excluded
Clinical laboratory values as specified below within 7 days before the first dose of study drug: Absolute neutrophil count ≥1,000/μL unless there is known HL marrow involvement; Platelet count ≥75,000/μL unless there is known HL marrow involvement; Total bilirubin <1.5 x ULN unless due to Gilbert syndrome; ALT or AST <3.0 x ULN (up to 5x ULN if due to HL in liver); Serum creatinine <2.0 mg/dL and/or creatinine clearance >30 mL/min (Cockcroft-Gault Equation); Hemoglobin ≥8 g/dL. Moderate or severe hepatic disease patients will be excluded based upon Child-Pugh criteria. Cardiovascular: see exclusion criteria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify